The Use of Non-Disclosure Agreements in Discrimination Cases

Compensation

In the past few years there has been a lot of discussion regarding sexual harassment in the workplace. In addition, stories regarding high profile figures such as Sir Phillip Green using non-disclosure agreements to cover up allegations of sexual harassment have come to light and the “me too” movement began.

Following this highly topical issue, the Women and Equalities Committee of the House of Commons recently published a report on the use of non-disclosure agreements in discrimination cases.

Top Tips for Employers: Providing References

Compensation

It is important that employers get the position right when it comes to employee references as an employer could potentially be liable to the employee and the new employer if they get it wrong. This article therefore includes some top tips for employers to consider when providing employee references.

Berry Smith Appointed By Tenovus Cancer Care

Leading UK Law Firm Appointed By Cancer Charity

Leading law firm, Berry Smith, has been appointed by Tenovus Cancer Care as its new legal representative.

The award-winning law firm, which has offices based across the UK, has been appointed by the Welsh charity to oversee its legal affairs following a competitive tender process completed at the end of 2018.

Berry Smith Shortlisted Again For Property Law Firm Of The Year

Berry Smith’s Commercial Property team has again been shortlisted for Property Law Firm of the Year at the Insider Wales Property Awards which are being held on Thursday 13th June 2019 at Cardiff City Hall.

The Commercial Property team is led by partners Martin Pursall and Chris Jones plus consultant Roger Berry, all of whom are recommended in the Legal 500 and Chambers & Partners legal directories. The department has a total of 10 fee earners plus 5 support staff.

Berry Smith Advises Yourgene Health Plc on the Acquisition of Elucigene

Berry Smith acted for AIM listed Yourgene Health Plc, the international molecular diagnostics group on its acquisition of Delta Diagnostics (UK) Limited, which trades as Elucigene, for a consideration of £9.2 million.

Elucigene is a Manchester based, molecular diagnostics manufacturer and developer, whose products focus on reproductive health and oncology, including products for cystic fibrosis and pre-natal aneuploidy screening.